memory in Alzheimer's disease: nootropics and compounds | sci-wiki

Eptastigmine

Eptastigmine was the Italian pharmaceutical company Mediolanum's long-acting redesign of physostigmine, an old carbamate cholinesterase inhibitor whose natural form works but wears off too fast to dose conveniently; adding a heptyl (seven-carbon) chain extended its duration of action enough to make once- or twice-daily dosing plausible for Alzheimer's patients. It moved through a full decade of pharmacology, toxicology, and clinical study, including efficacy trials that showed genuine cognitive benefit over placebo. Then hematology data caught up with it, reversible neutropenia and, in a subset of patients, agranulocytosis (a dangerous collapse in infection-fighting white blood cells) showed up during clinical trials at a rate high enough that regulators would not accept the risk, and the program was discontinued despite a decade of otherwise promising work.

reference

Nootropic

Metrifonate

Metrifonate has one of the stranger backstories in Alzheimer's drug history; it started life decades earlier as an antischistosomal insecticide-derived organophosphate sold as Bilarcil, and only later did researchers realize its slow, pseudo-irreversible acetylcholinesterase inhibition made it a candidate for boosting acetylcholine in Alzheimer's disease. Bayer ran it through large placebo-controlled Phase III trials where it produced genuine, statistically significant cognitive improvement over placebo, real efficacy that few of its competitors in this archive ever achieved. Then, deep into trials, roughly twenty patients developed neuromuscular dysfunction and life-threatening respiratory paralysis, apparently related to how chronic organophosphate exposure sensitizes patients to subsequent anesthetic or neuromuscular-blocking agents; Bayer halted the program and withdrew its FDA application in 1997, turning a drug with real cognitive benefit into a cautionary tale about repurposing organophosphates for chronic dosing.

reference

Nootropic

Tacrine

Tacrine earns its spot in this archive on historical weight rather than obscurity; it was the first drug the FDA ever approved for Alzheimer's disease, launched in 1993 under the name Cognex and proof-of-concept that the cholinergic hypothesis (that boosting acetylcholine could meaningfully help Alzheimer's symptoms) actually worked in the clinic, opening the door for donepezil, rivastigmine, and galantamine to follow. That legacy came with a real cost; tacrine caused liver-enzyme elevations in roughly a quarter to half of treated patients, serious enough that trial protocols required stopping the drug if ALT rose above three times normal, and while the injury was almost always reversible on discontinuation, the burden of mandatory liver monitoring made tacrine impractical once safer, twice-a-day alternatives without the hepatotoxicity reached the market. Its manufacturer discontinued marketing tacrine in the United States in 2013, quietly retiring the drug that had started the entire cholinesterase-inhibitor era.

reference

Nootropic

Velnacrine

Velnacrine is the main liver metabolite of tacrine, and Hoechst-Roussel developed it under the name Mentane hoping that using the metabolite directly, rather than relying on the body to convert tacrine into it, might dodge tacrine's notorious liver-toxicity problem. It did not; clinical trials found the same pattern of asymptomatic but concerning liver-enzyme elevations that had plagued tacrine, and researchers built a statistical risk model (called PROPP) just to try to predict which Alzheimer's patients would develop hepatotoxicity before exposing them to the drug. Hoechst-Roussel ultimately dropped velnacrine after regulators would not approve it on the safety data submitted, a case of a cleaner metabolite turning out to share its parent drug's core problem.

reference